SCHEMBL4837665

SCHEMBL4837665

CC(=O)NC1(c2ccccc2)CCN(CCC2c3ccccc3CCN2C(=O)c2ccc(Cl)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.43
DRD2 P14416 2/20 0.43
DRD4 P21917 1/20 0.43
TACR3 P29371 6/20 0.42
TACR2 P21452 2/20 0.42
TACR1 P25103 1/20 0.42
POLB P06746 1/20 0.42
HTR2C P28335 2/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
HRH1 P35367 1/20 0.41
HTR2B P41595 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
MEN1 O00255 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
OPRK1 P41145 2/20 0.39
OPRM1 P35372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839655 0.92 OPRM1 (0.46) TACR3TACR2TACR1POLBOPRK1
SCHEMBL4830126 0.92 TACR3 (0.45) DRD3DRD2TACR3POLB
SCHEMBL4836727 0.92 POLB (0.42) TACR3TACR2TACR1POLBKMT2A
SCHEMBL4837044 0.91 CYP2C19 (0.47) DRD3DRD2DRD4TACR3TACR2
SCHEMBL4837218 0.91 GRIN2C (0.46) TACR3TACR2TACR1
SCHEMBL4839456 0.89 TACR3 (0.44) DRD3DRD2DRD4TACR3TACR2
SCHEMBL4833088 0.86 GRIN2C (0.46) TACR2TACR1POLB
SCHEMBL4830055 0.85 CYP2C19 (0.49) DRD3TACR3MTNR1BALDH1A1
SCHEMBL4830031 0.84 CYP2C19 (0.51) TACR3TACR2TACR1MTNR1BALDH1A1
SCHEMBL4837151 0.84 CYP2C19 (0.47) TACR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 DRD3 1164/4885DRD2 684/4885DRD4 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.